Abstract
The amplification grade of oncogene c-erbB-2 was examined by the polymerase-chain-reaction-method in DNA's of 56 primary mammary carcinomas. 26 (46.4%) of these showed the amplified oncogene c-erbB-2. In the strongly amplified cases, the expression of the c-erbB-2 oncoprotein was verifiable immunohistochemically. Between the progesterone receptor status (PR) and the amplified c-erbB-2 oncogene there was a statistically proven dependency. No correlation was observed between the amplified c-erbB-2 oncogene and the epidermal growth-factor receptor (EGFR).
MeSH terms
-
Biomarkers, Tumor / genetics*
-
Breast / pathology
-
Breast Neoplasms / genetics*
-
Breast Neoplasms / pathology
-
Carcinoma, Intraductal, Noninfiltrating / genetics*
-
Carcinoma, Intraductal, Noninfiltrating / pathology
-
ErbB Receptors / genetics*
-
Female
-
Gene Amplification / genetics*
-
Humans
-
Immunoenzyme Techniques
-
Lymph Nodes / pathology
-
Lymphatic Metastasis
-
Neoplasm Staging
-
Proto-Oncogene Proteins / genetics*
-
Receptor, ErbB-2
-
Receptors, Estrogen / genetics*
-
Receptors, Progesterone / genetics*
Substances
-
Biomarkers, Tumor
-
Proto-Oncogene Proteins
-
Receptors, Estrogen
-
Receptors, Progesterone
-
ErbB Receptors
-
Receptor, ErbB-2